INS and early-onset autosomal dominant Alzheimer disease: In this sense, Rosenbloom, et al. [114] conducted a single-center, randomized, double-blind, placebo-controlled study to compare the efficacy of IN glulisine (fast-acting insulin) vs. placebo in N = 35 participants with memory impairment and Alzheimer’s disease.